Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 11, 2014, Pages

  Martinez Zapata, Maria José ^a   Martí Carvajal, Arturo J ^b   Solà, Ivan ^a   Pijoán, José I ^c,d   Buil Calvo, José A ^e   Cordero, Josep A ^f   Evans, Jennifer R ^g  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b Iberoamerican Cochrane Network   (Venezuela)

^c HOSPITAL DE CRUCES   (Spain)

^d BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f UNIVERSITAT RAMON LLULL   (Spain)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; BLINDNESS; CATARACT; CATARACT EXTRACTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTRAOCULAR HEMORRHAGE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; PAIN; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; QUALITY OF LIFE; RETINA DETACHMENT; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; VISION; VISUAL ACUITY; VITRECTOMY; DRUG EFFECTS; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VITREORETINOPATHY, PROLIFERATIVE;

ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; FEMALE; HUMANS; LIGHT COAGULATION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84922248690     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008721.pub2     Document Type: Review

References (111)

1. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009;116(10):1943-8.
2. Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011;118(11):2218-26.
3. Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study. Journal of Cataract and Refractive Surgery 2009;35(1):18-25.
4. Cho WB, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. British Journal of Ophthalmology 2010;94(7):858-63.
5. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009;29(4):516-22.
6. Di Lauro R, De Ruggiero P, Di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 2010;248(6):785-91.
7. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmology 2013;131(3):283-93.
8. El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clinical Ophthalmology 2008;2(4):709-16.
9. Ergur O, Bayhan HA, Kurkcuoglu P, Takmaz T, Gurdal C, Can I. Comparison of panretinal photocoagulation (PRP) with PRP plus intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy [Proliferatif diyabetik retinopati tedavisinde tek basina panretinal fotokoagulasyon (PRF) ile PRF ve intravitreal bevacizumab kombinasyonunun karsilastirilmasi]. Retina-Vitreus 2009;17(4):273-7.
10. Ernst BJ, García-Aguirre G, Oliver SC, Olson JL, Mandava N, Quiroz-Mercado H. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmologica 2012;90(7):e573-4.
11. Garcia-Aguirre G, Reyna-Castelan E, Torres M, Kon-Jara V, Quiroz-Mercado H. Intravitreal bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non-proliferative diabetic retinopathy: a contralateral eye study. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 5041.
12. Garcia-Aguirre G, Reyna-Castelán E, Torres-Soriano M, Kon-Jara V, Quiroz-Mercado H. Bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non-proliferative diabetic retinopathy: a contralateral eye study. Investigative Ophthalmology and Visual Science 2008;48:ARVO E-abstract 2750.
13. Farahvash MS, Majidi AR, Roohipoor R, Ghassemi F. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina 2011;31(7):1254-60.
14. Gonzalez VH, Vann VR. Treatment of proliferative diabetic retinopathy with intravitreal pegaptanib vs. panretinal photocoagulation. American Academy of Ophthalmology 2007:265.
15. Gonzalez VH, Vann VR, Banda RM, Giuliari GP, Guel DA. Pegaptanib sodium (Macugen®) versus panretinal photocoagulation (PRP) for the regression of proliferative diabetic retinopathy. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 4030.
16. Gonzalez VH, Vann VR, Banda-Gonzales RM. Selective VEGF Inhibition: effectiveness in modifying the progression of proliferative diabetic retinopathy. American Academy of Ophthalmology 2006:279.
17. González VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. British Journal of Ophthalmology 2009;93(11):1474-8.
18. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. European Journal of Ophthalmology 2008;18(2):263-9.
19. Modarres M, Nazari H. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. American Academy of Ophthalmology 2007:199.
20. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. European Journal of Ophthalmology 2009;19(5):848-52.
21. Preti RC, Vasquez Ramirez LM, Ribeiro Monteiro ML, Pelayes DE, Takahashi WY. Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial. Ophthalmologica 2013;230(1):1-8.
22. Preti RC, Vazquez L, Ribeiro M, Kehdi M, Pelayes DE, Yukihiko W. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial. British Journal of Ophthalmology 2014;97(7):885-9.
23. Lucena CR, Ramos Filho JA, Messias AM, Silva JA, Almeida FP, Scott IU, et al.Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy. Arquivos Brasileiros de Oftalmologia 2013;76(1):18-20.
24. Messias A, Ramos Filho JA, Messias K, Almeida FP, Costa RA, Scott IU, et al.Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy. Documenta Ophthalmologica 2012;124(3):225-36.
25. Ramos Filho JA, Messias A, Almeida FP, Ribeiro JA, Costa RA, Scott IU, et al.Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmologica 2011;89(7):e567-72.
26. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology 2008;246(6):837-42.
27. Sohn EH, He S, Kim LA, Salehi-Had H, Javaheri M, Spee C, et al.Angiofibrotic response to vascular endothelial growth factor Inhibition in diabetic retinal detachment. Archives of Ophthalmology 2012;130(9):1127-34.
28. Zaman Y, Rehman A, Fattah M. Intravitreal Avastin as an adjunct in patients with proliferative retinopathy undergoing pars plana vitrectomy. Pakistan Journal of Medical Sciences 2013;29(2):590-2.
29. Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, et al.Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009;116(5):921-6.
30. Fulda E, Ariza E, Lopez A, Graue F. Intravitreal bevacizumab and panretinal photocoagulation as combined treatment in proliferative diabetic retinopathy. Retina-Vitreus 2010;18(1):52-5.
31. Genovesi-Ebert F, Rizzo S, Di Bartolo E, Miniaci S, Vento A, Palla M, et al.Injection of intravitreal Avastin before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 5044.
32. Gonzalez VH, Macugen Diabetic Retinopathy Study Group. Pegaptanib in diabetic retinopathy: improvements in diabetic macular edema, retinal neovascularization, and diabetic retinopathy severity. American Academy of Ophthalmology 2006:192.
33. Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina 2010;30(5):761-4.
34. Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009;29(8):1134-40.
35. Ip MS, Domalpally A, Hopkins JH, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology 2012;130(9):1145-52.
36. Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmologica 2009;87(7):736-40.
37. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26(9):1006-13.
38. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina 2009;29(4):530-5.
39. López-López F, Gómez-Ulla F, Rodriguez-Cid MJ, Arias L. Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy. ISRN Ophthalmology 2012;2012:Article ID 267643.
40. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al.A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117(6):1078-86.
41. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Opthalmologica 2008;86(6):683-7.
42. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, et al.Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina 2008;28(1):36-40.
43. Shin YW, Lee YJ, Lee BR, Cho HY. Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean Journal of Ophthalmology 2009;23(4):266-72.
44. Stergiou P, Kokkinou D, Malamos K, Felekidis A, Kailari S. Varying doses of intravitreal bevacizumab (Avastin) for the treatment of proliferative diabetic retinopathy. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-abstract 1395.
45. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmologica 2008;86(4):385-9.
46. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009;29(6):768-74.
47. Zhou YY, Zhang RJ. Avastin combined with vitreous cavity injection of triamcinolone acetonide in treatment of diabetic retinopathy with macular edema. International Journal of Ophthalmology 2010;10(3):475-6.
48. EUCTR2013-003272-12-GB. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy. www.clinicaltrialsregister.eu/ctr-search/trial/2013-003272-12/GB (accessed 2 November 2014).
49. NCT01854593. Prospective randomized controlled study of intravitreal injection of 0.16 mg bevacizumab one day before surgery for proliferative diabetic retinopathy. clinicaltrials.gov/show/NCT01854593 (accessed 2 November 2014).
50. NCT01941329. Prospective, randomized, multicentre, open-label, phase II/III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy (PROTEUS). clinicaltrials.gov/show/NCT01941329 (accessed 2 November 2014).
51. NCT01976923. Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. clinicaltrials.gov/show/NCT01976923 (accessed 2 November 2014).
52. NCT01988246. Prevention of macular edema In patients with diabetic retinopathy undergoing cataract surgery. clinicaltrials.gov/show/NCT01988246 (accessed 2 November 2014).
53. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al.Retinopathy in diabetes. Diabetes Care 2006;27 Suppl 1:84-7.
54. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, et al.Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113(1):23-8.
55. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al.Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114(4):743-50.
56. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al.Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695.e1-15.
57. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26(3):352-4.
58. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. American Journal of Pathology 2001;159(3):993-1008.
59. Carmeliet P. Manipulating angiogenesis in medicine. Journal of Internal Medicine 2004;255(5):538-61.
60. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26(6):699-700.
61. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al.Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology 1996;114(9):1079-84.
62. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113(10):1706-12.
63. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al.A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57.
64. Davis MD, Fisher MR, Gagnon RE. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18. Investigative Ophthalmology & Visual Science 1998;39(2):233-52.
65. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
66. Anonymous. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Ophthalmology 1978;85(1):82-106.
67. Anonymous. Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report no. 5. Developments in Ophthalmology 1981;2:248-56.
68. Anonymous. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88(7):583-600.
69. Anonymous. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Archives of Ophthalmology 1985;103(11):1644-52.
70. Anonymous. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Archives of Ophthalmology 1985;103(12):1796-806.
71. Anonymous. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98 Suppl(5):786-806.
72. Anonymous. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98 Suppl(5):823-33.
73. Anonymous. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98 Suppl(5):766-85.
74. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. American Journal of Ophthalmology 1982;94(1):91-6.
75. Gilbert R, Kelly D, Cox A. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43(11):1360-7.
76. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
77. McMaster University. GRADEpro. 15 April 2014. McMaster University, 2014.
78. Haritoglou C, Kook D, Neibauer A, Wolf A, Priglinger S, Strauss R, et al.Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26(9):999-1005.
79. Hayward LM, Burden ML, Burden AC, Blackledge H, Raymond NT, Botha JL, et al.What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?. Diabetic Medicine 2002;19(1):27-3.
80. Higgins JPT, Green S. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
81. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T, et al.Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113(6):1020-7.
82. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of Ophthalmology 1984;102(4):520-6.
83. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260(19):2864-71.
84. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?. Archives of Internal Medicine 1989;149(11):2427-32.
85. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13(1):34-40.
86. Klein R, Klein BE. Blood pressure control and diabetic retinopathy. British Journal of Ophthalmology 2002;86(4):365-7.
87. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al.The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology 2002;109(7):1225-34.
88. Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnstrom K, Ludvigsson J. VISS Study Group. Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes. Diabetes Medicine 2002;19(11):924-31.
89. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al.Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109(5):920-7.
90. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. American Journal of Ophthalmology 2006;142(4):685-8.
91. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabetic Medicine 1995;12(6):482-7.
92. Moss SE, Klein R, Klein B. Ten-years incidence of visual loss in a diabetic population. Ophthalmology 1994;101(6):1061-70.
93. Moss S, Klein R, Klein BE. Cigarette smoking and ten-year progression in diabetic retinopathy. Ophthalmology 1996;103(9):1438-42.
94. Nauck M, Roth M, Tamm M, Eickleberg O, Weiland H, Stulz P, et al.Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. American Journal of Respiratory Cell and Molecular Biology 1997;16(4):398-406.
95. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al.Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004;82(11):844-51.
96. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
97. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114(10):1860-67.
98. Sennlaub F, Valamanesh F, Vazquez-Tello A, El-Asrar AM, Checchin D, Brault S, et al.Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 2003;108(2):198-204.
99. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al.Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmologica 2008;86(4):372-6.
100. Smith JM, Steel DHW. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD008214.pub2]
101. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26(3):275-8.
102. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
103. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
104. Anonymous. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317(7160):703-13.
105. Van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al.Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 2002;25(8):1320-5.
106. Van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al.Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Archives of Ophthalmology 2003;121(2):245-51.
107. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD007419.pub3]
108. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110(9):1677-82.
109. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al.Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's Archive for Clinical and Experimental Ophthalmology 2008;246(1):81-7.
110. Zhang ZH, Liu HY, Hernandez-Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, et al.Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. American Journal of Ophthalmology 2013;156(1):106-15.
111. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Pijoán JI, Buil-Calvo JA. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD008721]